Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:1286–1312.
   PubMed Web of Science ®Google Scholar
• Shitara K. Chemotherapy for advanced gastric cancer: future perspective in Japan. Gastric Cancer. 2017;20:102–110.
   PubMed Web of Science ®Google Scholar
• Roberto M, Romiti A, Onesti CE, et al. Evolving treatments for advanced gastric cancer: appraisal of the survival trend. Expert Rev Anticancer Ther. 2016;16:717–729.
   PubMed Web of Science ®Google Scholar
• Trougakos IP, Djeu JY, Gonos ES, et al. Advances and challenges in basic and translational research on clusterin. Cancer Res. 2009;69:403–406.
   PubMed Web of Science ®Google Scholar
• Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2000;6:1655–1663.
   PubMed Web of Science ®Google Scholar
• Muramaki M, So A, Hayashi N, et al. Chemosensitization of gemcitabine resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int. 2009;103:384–930.
   PubMed Web of Science ®Google Scholar
• Zellweger T, Miyake H, July LV, et al. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia. 2001;3:360–367.
   PubMed Web of Science ®Google Scholar
• So A, Sinnemann S, Huntsman D, et al. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther. 2005;4:1837–1849.
   PubMed Web of Science ®Google Scholar
• Engel RM, Chan WH, Nickless D, et al. Patient-derived colorectal cancer organoids upregulate revival stem cell marker genes following chemotherapeutic treatment. J Clin Med. 2020;9:pii: E128.
   PubMed Web of Science ®Google Scholar
• Ma J, Gao W, Gao J. sCLU as prognostic biomarker and therapeutic target in osteosarcoma. Bioengineered. 2019;10:229–239.
   PubMed Web of Science ®Google Scholar
• Zhang H, Kim JK, Edwards CA, et al. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 2005;7:909–915.
   PubMed Web of Science ®Google Scholar
• Pucci S, Mazzarelli P, Nucci C, et al. CLU “in and out”: looking for a link. Adv Cancer Res. 2009;105:93–113.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang K, Liu Z, et al. Secretory clusterin gene silencing enhances chemosensitivity of A549 cells to cisplatin through AKT and ERK1/2 pathways in vitro. Cell Physiol Biochem. 2014;33:1162–1175.
   PubMedGoogle Scholar
• Peng M, Deng J, Zhou S, et al. The role of Clusterin in cancer metastasis. Cancer Manage Res. 2019; 11:2405–2414.
   PubMed Web of Science ®Google Scholar
• Shiota M, Zardan A, Takeuchi A, et al. Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res. 2012;72(20):5261–5272.
   PubMed Web of Science ®Google Scholar
• Fischer KR, Durrans A, Lee S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472–476.
   PubMed Web of Science ®Google Scholar
• Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther. 2010;17:523–531.
   PubMed Web of Science ®Google Scholar
• Du F, Yu L, Wu Y, et al. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. Cell Death Dis. 2019;10:922.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen E, Tang Y, et al. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. Cell Death Dis. 2019;10:843.
   PubMed Web of Science ®Google Scholar
• Wu G, Cao L, Zhu J, et al. Loss of RBMS3 confers platinum resistance in epithelial ovarian cancer via activation of miR-126-5p/β-catenin/CBP signaling. Clin Cancer Res. 2019;25:1022–1035.
   PubMed Web of Science ®Google Scholar
• Fornari F, Pollutri D, Patrizi C, et al. In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3-mediated apoptosis. Clin Cancer Res. 2017;23:3953–3965.
   PubMed Web of Science ®Google Scholar
• Chen DD, Cheng JT, Chandoo A, et al. microRNA-33a prevents epithelial-mesenchymal transition, invasion, and metastasis of gastric cancer cells through the Snail/Slug pathway. Am J Physiol Gastrointest Liver Physiol. 2019;317:G147–G160.
   PubMed Web of Science ®Google Scholar
• Rezaei Z, Sebzari A, Kordi-Tamandani DM, et al. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in trastuzumab resistance of HER2-positive breast cancer cells and system biology approach to predict their targets involved in resistance. DNA Cell Biol. 2019;38:184–192.
   PubMed Web of Science ®Google Scholar
• Jin Y, Wang M, Hu H, et al. Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling. Int J Biol Macromol. 2018;117:445–453.
   PubMed Web of Science ®Google Scholar
• Alacam H, Akgun S, Akca H, et al. miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia. Psychiatry Res. 2016;245:200–206.
   PubMed Web of Science ®Google Scholar
• Wang J, Li L, Jiang M, et al. MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor. Clin Transl Oncol. 2017;19:1320–1328.
   PubMed Web of Science ®Google Scholar
• Zou J, Liao X, Zhang J, et al. Dysregulation of miR-195-5p/-218-5p/BIRC5 axis predicts a poor prognosis in patients with gastric cancer. J Biol Regul Homeost Agents. 2019;33:1377–1385.
   PubMed Web of Science ®Google Scholar
• Turanli S, Atalay C, Berberoglu U, et al. Adjuvant chemoradiation versus chemotherapy for stage III gastric cancer after surgery with curative intent. J Cancer Res Ther. 2015;11:369–374.
   PubMed Web of Science ®Google Scholar
• Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33:3130–3136.
   PubMed Web of Science ®Google Scholar
• Dassen AE, Lemmens VE, van de Poll-franse LV, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer. 2010;46:1101–1110.
   PubMed Web of Science ®Google Scholar
• Stewart C, Chao J, Chen YJ, et al. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol. 2019;4:42.
   PubMed Web of Science ®Google Scholar
• González CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 2012;130:745–753.
   PubMed Web of Science ®Google Scholar
• Pucci S, Bonanno E, Pichiorri F, et al. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene. 2004;23:2298–2304.
   PubMed Web of Science ®Google Scholar
• Sowery RD, Hadaschik BA, So AI, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 2008;102:389–397.
   PubMed Web of Science ®Google Scholar
• Yom CK, Woo HY, Min SY, et al. Clusterin overexpression and relapse-free survival in breast cancer. Anticancer Res. 2009;29:3909–3912.
   PubMed Web of Science ®Google Scholar
• García-Aranda M, Téllez T, Muñoz M, et al. Clusterin inhibition mediates sensitivity to chemotherapy and radiotherapy in human cancer. Anticancer Drugs. 2017;28:702–716.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Zoubeidi A. Clusterin as a therapeutic target. Expert Opin Ther Targets. 2017;21:201–213.
   PubMed Web of Science ®Google Scholar
• Koltai T. Clusterin: a key player in cancer chemoresistance and its inhibition. Onco Targets Ther. 2014;447. DOI:10.2147/OTT.S58622
   PubMed Web of Science ®Google Scholar
• Wu K, Xie D, Zou Y, et al. The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res. 2013;19:4740–4749.
   PubMed Web of Science ®Google Scholar
• Zheng W, Yao M, Wu M, et al. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis. J Transl Med. 2020;18(1):447–456.
   PubMed Web of Science ®Google Scholar
• Forouzan Jahromi Z, Javeri A, Fakhr Taha M. Tumor suppressive effects of the pleiotropically acting miR-195 in colorectal cancer cells. Excli J. 2019;18:243–252.
   PubMed Web of Science ®Google Scholar
• Luo J, Pan J, Jin Y, et al. MiR-195-5p inhibits proliferation and induces apoptosis of non-small cell lung cancer cells by targeting CEP55. Onco Targets Ther. 2019;12:11465–11474.
   PubMed Web of Science ®Google Scholar